VYNE Q3 2023 Earnings Report
Key Takeaways
VYNE Therapeutics reported its Q3 2023 financial results, highlighting a transformative $88.2 million capital raise to fund BET inhibitor programs through 2025. The company is progressing with Phase 2b preparatory activities for VYN201 in nonsegmental vitiligo and is on track for VYN202 IND submission by year-end 2023.
Completed a transformative capital raise of $88.2 million from leading healthcare investors, providing funding through the end of 2025.
Progressing with Phase 2b preparatory activities for VYN201 in nonsegmental vitiligo following positive Phase 1b results.
On track for VYN202 IND submission by year-end 2023, with plans to begin Phase 1a trial in Q1 2024.
Anticipates cash and cash equivalents will be sufficient to fund operations through the end of 2025.
VYNE
VYNE
Forward Guidance
VYNE Therapeutics anticipates that its cash and cash equivalents and restricted cash as of September 30, 2023, together with the gross proceeds from the PIPE, will be sufficient to fund its operations through the end of 2025.